Invitae Corp. (NVTA)

20.52
NYSE : Health Services
Prev Close 19.23
Day Low/High 18.61 / 20.88
52 Wk Low/High 7.08 / 26.77
Avg Volume 1.67M
Exchange NYSE
Shares Outstanding 89.84M
Market Cap 1.73B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Invitae Announces ID YOUR IRD Program To Expand Access To Genetic Testing For Inherited Retinal Disorders

Invitae Announces ID YOUR IRD Program To Expand Access To Genetic Testing For Inherited Retinal Disorders

-Genetic testing can identify causes of rare, progressive eye disorders-

Invitae Introduces New Service To Make It Easier For Consumers To Receive The Medical Genetic Testing That Experts Trust

Invitae Introduces New Service To Make It Easier For Consumers To Receive The Medical Genetic Testing That Experts Trust

-- Provides high-quality, affordable, clinician-guided genetic testing to inform healthcare decisions --

Research From Invitae Demonstrates The Importance Of Germline Multigene Panel Testing In Guiding Therapy For Expanding Groups Of Cancer Patients

Research From Invitae Demonstrates The Importance Of Germline Multigene Panel Testing In Guiding Therapy For Expanding Groups Of Cancer Patients

- Data to be presented at the American Society of Clinical Oncology Annual Meeting -

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to...

Invitae To Present At The 2019 William Blair Growth Stock Conference

Invitae To Present At The 2019 William Blair Growth Stock Conference

SAN FRANCISCO, May 22, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock...

Invitae To Present At The UBS Global Healthcare Conference

Invitae To Present At The UBS Global Healthcare Conference

SAN FRANCISCO, May 15, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare...

New Study From Invitae Highlights The Importance Of Multigene Genetic Testing For Uterine Cancer Patients

New Study From Invitae Highlights The Importance Of Multigene Genetic Testing For Uterine Cancer Patients

Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

NVTA December 20th Options Begin Trading

NVTA December 20th Options Begin Trading

Investors in Invitae Corp saw new options begin trading today, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Invitae To Announce First Quarter 2019 Financial Results On May 7, 2019

Invitae To Announce First Quarter 2019 Financial Results On May 7, 2019

SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast...

FH Foundation Expands FIND FH® To Speed Diagnosis Of Individuals With Homozygous Familial Hypercholesterolemia

FH Foundation Expands FIND FH® To Speed Diagnosis Of Individuals With Homozygous Familial Hypercholesterolemia

Confirmatory FH Genetic Testing and Counseling Offered through Invitae and Genome Medical

Research Underscores Need For Updated Guidelines To Include Multigene Testing For Cancer Patients

Research Underscores Need For Updated Guidelines To Include Multigene Testing For Cancer Patients

- Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting -

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'

NVTA Crosses Above Average Analyst Target

NVTA Crosses Above Average Analyst Target

In recent trading, shares of Invitae Corp have crossed above the average analyst 12-month target price of $22.96, changing hands for $22.97/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Invitae To Present At The Oppenheimer 29th Annual Healthcare Conference

Invitae To Present At The Oppenheimer 29th Annual Healthcare Conference

SAN FRANCISCO, March 14, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare...

Do Your Homework: Cramer's 'Mad Money' Recap (Tuesday 3/12/19)

Do Your Homework: Cramer's 'Mad Money' Recap (Tuesday 3/12/19)

Jim Cramer looks at Boeing, Dick's Sporting Goods and more -- and shows investors how to really understand the markets and stock-picking.

Charles Schwab, Invitae, Weibo: 'Mad Money' Lightning Round

Charles Schwab, Invitae, Weibo: 'Mad Money' Lightning Round

Jim Cramer weighs in on Charles Schwab, Invitae, Weibo, Alibaba, Charles River Labs, AeroVironment, Ormat Technologies.

Invitae Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Invitae Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters' option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.

Invitae Announces Pricing Of Public Offering Of Common Stock

Invitae Announces Pricing Of Public Offering Of Common Stock

SAN FRANCISCO, March 5, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.

Invitae Announces Proposed Public Offering Of Common Stock

Invitae Announces Proposed Public Offering Of Common Stock

SAN FRANCISCO, March 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.

Behind The Seizure™ Program Expansion Helps Speed The Diagnosis Of Genetic Epilepsy In Younger Children Experiencing Unprovoked Seizures

Behind The Seizure™ Program Expansion Helps Speed The Diagnosis Of Genetic Epilepsy In Younger Children Experiencing Unprovoked Seizures

--Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure--

Electric Car Stocks Get a Charge as Pockets of Momentum Develop

Electric Car Stocks Get a Charge as Pockets of Momentum Develop

When the indices aren't offering much opportunity money flows into individual speculative names.

3 Small Biotechs to Watch as Earnings Season Winds Down

3 Small Biotechs to Watch as Earnings Season Winds Down

One already is up nicely on its results, while the other two should issue reports of interest in the next few days.

Invitae To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Invitae To Present At The 8th Annual SVB Leerink Global Healthcare Conference

SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare...

Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information In Early Pregnancy

Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information In Early Pregnancy

-- In Combination with Carrier Screening, NIPS Provides Affordable, Streamlined Access to Genetic Testing for Parents-to-Be --

New Study Finds Disease-Causing Variants More Common In Men With Prostate Cancer Than Previously Thought

New Study Finds Disease-Causing Variants More Common In Men With Prostate Cancer Than Previously Thought

-- Largest Dataset of Prostate Cancer Patients Shows 17% Have Increased Risk Based on Genetic Analysis --

Invitae To Announce Fourth Quarter And Year-end 2018 Financial Results On February 19, 2019

Invitae To Announce Fourth Quarter And Year-end 2018 Financial Results On February 19, 2019

SAN FRANCISCO, Jan. 29, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will...

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

Cronos, Fortinet and Dominion: 'Mad Money' Lightning Round

Cronos, Fortinet and Dominion: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cronos, Fortinet, Dominion Energy and more.

TheStreet Quant Rating: D (Sell)